Page 142 - MNU-PM502- Pharmaeutical Microbiology Theoritical Book

Pharm D- Clinical Pharmacy Program Third Level Pharmaceutical Microbiology& Antimicrobials (PM 502)

• Depending on the genotype, sofosbuvir is often used in combination with
other antivirals

➢ Sofosbuvir +ribavirin (Oral dual therapy) for genotypes 2 and 3.

➢ Sofosbuvir + peginterferon+ ribavirin (Triple therapy): genotypes 1,

4

➢ Sofosbuvir + Ledipasvir (tradename Harvoni): genotypes 1, 4, 5, and 6

with or without Ribavirin

➢ Sofosbuvir + Velpatasvir (tradename Epclusa): all genotypes

D. Antiretroviral Agents

1. Entry Inhibitors

2. Reverse Transcriptase Inhibitors

Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI)

3. Integrase inhibitors

4. Protease Inhibitors

1. Fusion or entry inhibitor Inhibitors

Enfuvirtide, Maraviroc

2. Reverse Transcriptase Inhibitor

129